TRINETRA › Sectors › Healthcare
Akums Drugs and Pharmaceuticals Limited (AKUMS) — share price, P/E and fundamentals
Akums Drugs and Pharmaceuticals Limited (NSE: AKUMS) closed at ₹735.00 on 30 Oct 2026, +59.2% over one year, against a 52-week range of ₹409.30 – ₹838.80.
In the quarter ended 30 Jun 2026 (consolidated, filed 8 Aug 2026) it reported revenue of ₹1,167 cr and net profit of ₹100 cr, a 8.6% net margin; revenue grew 13.9% and profit grew 45.6% year on year.
On four consecutive filed quarters its trailing P/E is 38.6; since 26 May 2025 its own P/E has ranged from 30.9 to 3,96,402.1 (median 2,80,384.4), and today's reading is higher than 12% of those 354 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 12.1%, ROCE 15.1%, debt-to-equity 0.02, Piotroski F-score 6 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 21% of 63 sector peers; PBT margin higher than 21% of 63 sector peers; ROE higher than 41% of 63 sector peers.
Key figures
| Last close | ₹735.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -10.1% / +42.9% / +59.2% |
| 52-week low – high | ₹409.30 – ₹838.80 |
| Market capitalisation | ₹11,253 cr |
| Trailing P/E | 38.6 |
| Price / book | 3.40 |
| EV / EBITDA | 16.1 |
| Earnings yield | 2.6% |
| TTM EPS | ₹19.05 |
| TTM net profit | ₹292 cr |
| Quarter revenue | ₹1,167 cr |
| Quarter net profit | ₹100 cr |
| Net margin | 8.6% |
| Revenue growth (YoY) | +13.9% |
| Profit growth (YoY) | +45.6% |
| Return on equity | 12.1% |
| ROCE | 15.1% |
| Debt / equity | 0.02 |
| Current ratio | 3.25 |
| Free cash flow | ₹951 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹19.8 cr |
Against Healthcare peers
| Metric | AKUMS | Peer median | Percentile |
|---|---|---|---|
| Net margin | 8.57 | 12.89 | 21 |
| PBT margin | 11.93 | 17.68 | 21 |
| ROE | 12.07 | 13.87 | 41 |
| ROCE | 15.07 | 17.26 | 37 |
| Debt / equity | 0.02 | 0.11 | 34 |
| Cash conversion | 4.61 | 1.25 | 97 |
| Trailing P/E | 38.58 | 43.26 | 39 |
| P/B | 3.40 | 6.02 | 18 |
Questions
What is the P/E ratio of Akums Drugs and Pharmaceuticals Limited?
Akums Drugs and Pharmaceuticals Limited's trailing P/E is 38.6, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 26 May 2025 its P/E has ranged 30.9–3,96,402.1.
What were Akums Drugs and Pharmaceuticals Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Akums Drugs and Pharmaceuticals Limited reported revenue of ₹1,167 cr and net profit of ₹100 cr (consolidated), filed with the exchange on 8 Aug 2026.
What is Akums Drugs and Pharmaceuticals Limited's ROE?
Return on equity is 12.1% based on the balance sheet dated 31 Mar 2026.
Does Akums Drugs and Pharmaceuticals Limited have debt?
Debt-to-equity is 0.02 on the balance sheet dated 31 Mar 2026.
What is AKUMS's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, AKUMS traded between ₹409.30 and ₹838.80.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.